BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16133051)

  • 1. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome.
    Nozu K; Iijima K; Fujisawa M; Nakagawa A; Yoshikawa N; Matsuo M
    Pediatr Nephrol; 2005 Nov; 20(11):1660-3. PubMed ID: 16133051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis.
    Yabu JM; Ho B; Scandling JD; Vincenti F
    Am J Transplant; 2008 Jan; 8(1):222-7. PubMed ID: 17979998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report.
    Kolonko A; Piecha G; Więcek A
    Transplant Proc; 2016 Nov; 48(9):3092-3094. PubMed ID: 27932154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis.
    Rodríguez-Ferrero M; Ampuero J; Anaya F
    Transplant Proc; 2009; 41(6):2406-8. PubMed ID: 19715934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis.
    Gossmann J; Scheuermann EH; Porubsky S; Kachel HG; Geiger H; Hauser IA
    Transpl Int; 2007 Jun; 20(6):558-62. PubMed ID: 17433091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.
    Verschuuren EA; Stevens SJ; van Imhoff GW; Middeldorp JM; de Boer C; Koëter G; The TH; van Der Bij W
    Transplantation; 2002 Jan; 73(1):100-4. PubMed ID: 11792987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [No effect of rituximab in pediatric case of severe nephrotic syndrome and focal segmental glomeruloslerosis accompanied by renal insufficiency].
    Hyla-Klekot L; Grenda R; Pulcer B
    Pol Merkur Lekarski; 2008 Dec; 25(150):519-22. PubMed ID: 19205386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of rituximab on a native kidney and a post-transplant kidney with recurrence of focal segmental glomerulosclerosis.
    Ino A; Kaori S; Takei T; Nitta K
    CEN Case Rep; 2020 Aug; 9(3):195-199. PubMed ID: 31997159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab.
    Suri M; Tran K; Sharma AP; Filler G; Grimmer J
    Int Urol Nephrol; 2008; 40(3):807-10. PubMed ID: 18491215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports.
    Kamar N; Faguer S; Esposito L; Guitard J; Nogier MB; Durand D; Rostaing L
    Clin Nephrol; 2007 Apr; 67(4):250-4. PubMed ID: 17474562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for post-transplant recurrences of FSGS.
    Bayrakci US; Baskin E; Sakalli H; Karakayali H; Haberal M
    Pediatr Transplant; 2009 Mar; 13(2):240-3. PubMed ID: 18822107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early recurrence of nephrotic syndrome (immunoglobulin m nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin, and rituximab.
    Westphal S; Hansson S; Mjörnstedt L; Mölne J; Swerkersson S; Friman S
    Transplant Proc; 2006 Oct; 38(8):2659-60. PubMed ID: 17098031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
    Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence of nephrotic proteinuria in children with focal segmental glomerulosclerosis after renal transplantation treated with plasmapheresis and immunoadsorption: case reports.
    Fencl F; Simková E; Vondrák K; Janda J; Chadimová M; Stejskal J; Seeman T
    Transplant Proc; 2007 Dec; 39(10):3488-90. PubMed ID: 18089416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab.
    Marasà M; Cravedi P; Ruggiero B; Ruggenenti P
    BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25155494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
    Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
    Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.
    Jain AB; Marcos A; Pokharna R; Shapiro R; Fontes PA; Marsh W; Mohanka R; Fung JJ
    Transplantation; 2005 Dec; 80(12):1692-8. PubMed ID: 16378063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
    Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature.
    Peters HP; van de Kar NC; Wetzels JF
    Neth J Med; 2008 Nov; 66(10):408-15. PubMed ID: 19011266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.